Nonhuman Primate Studies of Tenofovir and UC781

替诺福韦和 UC781 的非人类灵长类动物研究

基本信息

批准号：
7898232
负责人：
DOROTHY L PATTON
金额：
$ 37.82万
依托单位：
MAGEE-WOMEN'S RES INST AND FOUNDATION
依托单位国家：
美国
项目类别：
财政年份：
2010
资助国家：
美国
起止时间：
2010-06-15 至 2015-05-31
项目状态：
已结题

来源：
https://reporter.nih.gov/project-details/7898232
关键词：
AIDS/HIV problem Adult Animals Anti-Bacterial Agents Anti-Retroviral Agents Antibodies Antiviral Agents Biopsy Biopsy Specimen CD4 Lymphocyte Count Cell secretion Cervical Characteristics Clinical Research Clinical Trials Collaborations Contrast Media Cytology DNA Data Dosage Forms Drug Formulations Drug Kinetics Ecosystem Epithelium Exposure to Female Film Gel Genital system Goals Gram&apos s stain HIV High Pressure Liquid Chromatography Hour Human Image Infection Infection prevention Irrigation Kinetics Life Local Microbicides Macaca Macaca nemestrina Magnetic Resonance Imaging Measurement Measures Microbiology Modeling Monitor MultiHance Nucleotides Peripheral Blood Mononuclear Cell Pharmaceutical Preparations Plasma Prevention Preventive RNA Research Reverse Transcriptase Inhibitors Safety Sampling Serum Sexually Transmitted Diseases Site Swab System Tenofovir Testing Tissues U-Series Cooperative Agreements UC 781 Vagina Vaginal Douching Vaginal Gel Viral Load result Virus Woman efficacy testing in vivo microbicide non-nucleoside reverse transcriptase inhibitors nonhuman primate novel pandemic disease pharmacokinetic characteristic preclinical safety preclinical study protective effect reproductive routine Bacterial stain simian human immunodeficiency virus trafficking

项目摘要

Research efforts to develop topical microbicides for intravaginal use for the prevention of sexually transmitted infections (STI) including HIV have been ongoing for over a decade. In the past year an estimated 4.3 million people became newly infected with HIV. Women now represent almost half of all adults living with HIV/AIDS. The need for a female controlled STI preventive product is well understood. Preclinical safety and efficacy testing of topical microbicide products must be performed prior to human use to assess the product's effects on the vaginal ecosystem and to assess potential anti-HIV activity. We have developed a useful model to evaluate the safety of topical microbicide products after vaginal use in the pigtailed macaque. We have used this model to study the effects of single and repeated applications of microbicides on vaginal microflora and epithelium. We have conducted preclinical safety and pharmacokinetic studies of vaginal gel formulations containing UC781 ( 1% and 0.1%) and tenofovir (1%) in this macaque model. In addition, we have the ability to image (MRI) product dispersal and transport in the female reproductive tract. In this proposed cooperative agreement, a novel delivery system for topical microbicides, vaginal films, will be compared to vaginal gel formulations. We will use our macaque model to assess safety, dispersal and pharmacokinetic characteristics of various film formulations containing UC781 and/or tenofovir, and compare these findings to those compiled for gel formulations. Finally, we will assess the efficacy of each of the developed film products using a macaque model for RT-SHIV infection. These studies will in part guide the optimization of a combination topical microbicide delivery system.

开发用于阴道内预防性行为的局部杀菌剂的研究工作包括艾滋病毒在内的传播感染（STI）已经持续了十多年。在过去的一年里据估计，有 430 万人新感染艾滋病毒。女性现在几乎占所有成年人的一半感染艾滋病毒/艾滋病。对女性控制的性传播感染预防产品的需求是众所周知的。临床前局部杀菌剂产品的安全性和功效测试必须在人类使用前进行评估该产品对阴道生态系统的影响并评估潜在的抗艾滋病毒活性。我们开发了一个有用的模型来评估阴道使用后局部杀菌剂产品的安全性辫子猕猴我们使用这个模型来研究单次和重复应用的效果对阴道微生物群和上皮细胞的杀微生物剂。我们进行了临床前安全性和含有 UC781（1% 和 0.1%）和替诺福韦（1%）的阴道凝胶制剂的药代动力学研究这个猕猴模型。此外，我们有能力对产品在环境中的分散和运输进行成像 (MRI) 女性生殖道。在这项拟议的合作协议中，一种新型的局部杀菌剂递送系统——阴道膜，将与阴道凝胶制剂进行比较。我们将使用我们的猕猴模型来评估安全性、分散性和含有UC781和/或替诺福韦的各种膜制剂的药代动力学特征，并进行比较这些发现与为凝胶配方编制的结果相结合。最后，我们将评估每种方法的功效使用猕猴模型开发用于 RT-SHIV 感染的薄膜产品。这些研究将部分指导组合局部杀菌剂输送系统的优化。